MX2020007880A - Anticuerpos de mica/b y metodos de uso. - Google Patents

Anticuerpos de mica/b y metodos de uso.

Info

Publication number
MX2020007880A
MX2020007880A MX2020007880A MX2020007880A MX2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A
Authority
MX
Mexico
Prior art keywords
mica
antibodies
methods
chain domains
well
Prior art date
Application number
MX2020007880A
Other languages
English (en)
Inventor
Xin Du
Neil Gibson
Justin Chapman
Original Assignee
Cullinan Mica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Mica Corp filed Critical Cullinan Mica Corp
Publication of MX2020007880A publication Critical patent/MX2020007880A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente anticuerpos que se unen específicamente a MICA/B que tiene dominios de cadena pesada variables (VH), dominios de cadena ligera variables (VL), y regiones determinadoras de complementariedad descritas en la presente, así como métodos y usos de los mismos.
MX2020007880A 2018-01-25 2019-01-24 Anticuerpos de mica/b y metodos de uso. MX2020007880A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2020007880A true MX2020007880A (es) 2021-05-14

Family

ID=67396240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007880A MX2020007880A (es) 2018-01-25 2019-01-24 Anticuerpos de mica/b y metodos de uso.

Country Status (10)

Country Link
US (2) US20210047417A1 (es)
EP (1) EP3743109A4 (es)
JP (2) JP7458993B2 (es)
KR (1) KR102731953B1 (es)
CN (1) CN112566659A (es)
AU (1) AU2019211411B2 (es)
BR (1) BR112020015142A2 (es)
IL (1) IL276187B2 (es)
MX (1) MX2020007880A (es)
WO (1) WO2019147863A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR102832008B1 (ko) 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN116547301A (zh) * 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN119998318A (zh) * 2022-04-08 2025-05-13 D2M生物治疗有限公司 抗mica/b抗体及其用途
CN116789823A (zh) * 2023-04-04 2023-09-22 浙江大学 用于检测mica脱落片段的结构域特异性抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
HRP20220890T1 (hr) * 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
EP3471761A2 (en) * 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof

Also Published As

Publication number Publication date
IL276187B2 (en) 2026-06-01
KR20200115545A (ko) 2020-10-07
KR102731953B1 (ko) 2024-11-20
WO2019147863A3 (en) 2019-10-24
EP3743109A4 (en) 2021-11-10
CA3089478A1 (en) 2019-08-01
EP3743109A2 (en) 2020-12-02
US20240067731A1 (en) 2024-02-29
IL276187B1 (en) 2026-02-01
AU2019211411A1 (en) 2020-08-20
JP7458993B2 (ja) 2024-04-01
CN112566659A (zh) 2021-03-26
RU2020128010A (ru) 2022-02-25
JP2021511387A (ja) 2021-05-06
WO2019147863A2 (en) 2019-08-01
AU2019211411B2 (en) 2025-11-27
US20210047417A1 (en) 2021-02-18
BR112020015142A2 (pt) 2021-01-05
IL276187A (en) 2020-09-30
JP2024038169A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
CO2019009365A2 (es) Anticuerpos anti-lag3
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
SA517381604B1 (ar) أجسام مضادة ديمرية غير متجانسة جديدة
MX380937B (es) Anticuerpos dobles especificos.
CU20160118A7 (es) Moléculas de anticuerpo que se unen a tim-3
ECSP22097203A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
CL2019001352A1 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo.
EA201691321A1 (ru) Антитела и способы их применения
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
WO2019147863A3 (en) Mica/b antibodies and methods of use
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
ZA202101258B (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX394735B (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
ECSP22097197A (es) Anticuerpos que se dirigen a un complejo que comprende hla–i no clásico y neoantígeno y sus métodos de uso
EA201600277A1 (ru) Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh